Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $326.25.

Several equities analysts recently weighed in on KRYS shares. Chardan Capital raised their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Citigroup lifted their price target on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. TD Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Guggenheim boosted their price objective on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th.

Insider Activity

In related news, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. The trade was a 39.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the transaction, the insider owned 1,403,155 shares in the company, valued at $369,324,427.55. This trade represents a 1.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,164 shares of company stock valued at $34,538,578 over the last ninety days. 13.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Several hedge funds have recently bought and sold shares of the stock. UMB Bank n.a. increased its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares in the last quarter. Optimize Financial Inc boosted its holdings in Krystal Biotech by 1.4% in the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC boosted its holdings in Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after buying an additional 41 shares during the period. Regal Investment Advisors LLC increased its stake in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after buying an additional 44 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its stake in Krystal Biotech by 2.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock worth $524,000 after buying an additional 55 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.8%

Shares of NASDAQ:KRYS opened at $260.95 on Friday. The firm has a 50 day moving average of $265.14 and a 200-day moving average of $232.38. The stock has a market capitalization of $7.63 billion, a PE ratio of 38.09 and a beta of 0.54. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. On average, research analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.